|
INCREASED RISK OF MYOCARDIAL DEPRESSION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
MEXILETINE ABSORPTION IS INCREASED BY THE DRUG
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
LIGNOCAIN TOXICITY MAY BE PRECIPITATED DUE TO CO-ADMINISTRATION
|
LIGNOCAIN TOXICITY MAY BE PRECIPITATED DUE TO CO-ADMINISTRATION
|
LIGNOCAIN TOXICITY MAY BE PRECIPITATED DUE TO CO-ADMINISTRATION
|
LIGNOCAIN TOXICITY MAY BE PRECIPITATED DUE TO CO-ADMINISTRATION
|
LIGNOCAIN TOXICITY MAY BE PRECIPITATED DUE TO CO-ADMINISTRATION
|
LIGNOCAIN TOXICITY MAY BE PRECIPITATED DUE TO CO-ADMINISTRATION
|
LIGNOCAIN TOXICITY MAY BE PRECIPITATED DUE TO CO-ADMINISTRATION
|
LIGNOCAIN TOXICITY MAY BE PRECIPITATED DUE TO CO-ADMINISTRATION
|
LIGNOCAIN TOXICITY MAY BE PRECIPITATED DUE TO CO-ADMINISTRATION
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
RIFAPENTINE INDUCES METABOLISM OF THE OTHER DRUG CAUSING DECREASED PLASMA LEVELS
|
POSSIBLE INCREASE IN SERIOUS TOXICITY WHEN AMIODARONE IS USED WITH OTHER ANTIARRHYTHMICS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|